scispace - formally typeset
Journal ArticleDOI

Continuous midazolam versus diazepam infusion for refractory convulsive status epilepticus.

TLDR
Continuous midazolam and diazepam infusions were equally effective for control of refractory status epilepticus, however, midrazolam was associated with more seizure recurrence and higher mortality in refractors predominantly caused by central nervous system infections.
Abstract
The objective of this study was to compare the efficacy of continuous midazolam and diazepam infusion for the control of refractory status epilepticus. An open-label, randomized control study was undertaken at the Pediatric Emergency and Intensive Care Service of a multidisciplinary teaching and referral hospital. Subjects included 40 children, 2 to 12 years of age, with refractory status epilepticus (motor seizures uncontrolled after two doses of diazepam, 0.3 mg/kg per dose, and phenytoin infusion, 20 mg/kg). Either continuous midazolam (n = 21) or diazepam infusion (n = 19) in incremental doses was administered. The primary outcome measure was the proportion of children in each group with successful control of refractory status epilepticus. The secondary outcome measure was the time to control seizure activity, recurrence of seizure after initial control, if any, the frequency of hypotension, and the need for ventilation. The two groups were similar in age (mean +/- SD = 4.9 +/- 43.6 months) and etiology. Twenty-three (57.5%) patients had acute central nervous system infection. Refractory status epilepticus was controlled in 18 (86%) and 17 (89%) patients in the midazolam and diazepam groups, respectively (P = not significant). The median time to seizure control was 16 minutes in both groups, but in the midazolam group, seizures recurred in more children (57% versus 16% in diazepam group; P .05). Continuous midazolam and diazepam infusions were equally effective for control of refractory status epilepticus. However, midazolam was associated with more seizure recurrence and higher mortality in refractory status epilepticus predominantly caused by central nervous system infections.

read more

Citations
More filters
Journal ArticleDOI

The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol

TL;DR: There is an urgent need for the establishment of a database of outcomes of individual therapies for super-refractory status epilepticus, which is an uncommon but important clinical problem with high mortality and morbidity rates.
Journal ArticleDOI

Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.

TL;DR: Among these BZDs, clorazepate has a unique profile that includes a long half‐life of its active metabolite and slow onset of tolerance, which could theoretically help minimize adverse events.
Journal ArticleDOI

Status epilepticus: pathophysiology and management in adults

TL;DR: In this article, the authors identify three phases of generalised convulsive status epilepticus, which they call impending, established, and subtle, and suggest that prehospital treatment is beneficial, that therapeutic drugs should be used in rapid sequence according to a defined protocol, and that refractory status epilepsy should be treated with general anaesthesia.
Journal ArticleDOI

The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy.

TL;DR: An approach to therapy, divided into first-line, second-line and third-line therapy, is suggested on the basis of this outcome evaluation, noting the importance of treatments directed at the cause of the status epilepticus, and of supportive ITU care.
References
More filters
Journal ArticleDOI

PRISM III: An updated Pediatric Risk of Mortality score

TL;DR: A third-generation pediatric physiology-based score for mortality risk, Pediatric Risk of Mortality III (PRISM III), was developed and validated and resulted in several improvements over the original PRISM.
Book

Status Epilepticus

Journal ArticleDOI

Midazolam: pharmacology and uses.

TL;DR: Advantages of midazolam over thiopental are those of the more versatile pharmacologic properties of a benzodiazepine compared with a barbiturate such as amnestic and anxiolytic properties.
Journal ArticleDOI

Low morbidity and mortality of status epilepticus in children

TL;DR: The mortality and incidence of sequelae following status epilepticus was low and primarily a function of etiology, and age did not affect outcome within each cause.
Journal ArticleDOI

Treatment of refractory status epilepticus with propofol: Clinical and pharmacokinetic findings

TL;DR: Propofol is compared with high‐dose barbiturates in the treatment of refractory status epilepticus (RSE) and a protocol for the administration of propofol in RSE in adults is proposed, correlating prop ofol's effect with plasma levels.
Related Papers (5)